Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist, and a selective ER degrader (SERD). OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase4 (CDK4)/6 demonstrated robust tumour shrinkage in several xenograft models, including a breast cancer brain metastasis model.

Drug & Indication	Stage & Event	Catalyst Date
OP-1250 (CER antagonist) Details Metastatic breast cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OP-1250 +palbociclib Details Metastatic breast cancer, Breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OP-1250 +ribociclib Details Breast cancer, Metastatic breast cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.

Drug Pipeline

Powered by